Humacyte Shares Rise After Phase 3 Data Show Bioengineered Vessel Benefits for Women on Dialysis
Humacyte Inc. reported positive results from its V012 Phase 3 study showing that its acellular tissue engineered vessel (ATEV) delivered longer catheter-free periods and fewer infections for women on dialysis compared with arteriovenous fistula (AV fistula). The data were presented at the Vascular Annual Meeting in Boston and preceded a modest rise…